Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

PWWP2A: A novel mitosis link?

Link S, Hake SB.

Cell Cycle. 2017 Oct 18;16(20):1849-1850. doi: 10.1080/15384101.2017.1372523. Epub 2017 Sep 21. No abstract available.

PMID:
28933988
2.

Multivalent binding of PWWP2A to H2A.Z regulates mitosis and neural crest differentiation.

Pünzeler S, Link S, Wagner G, Keilhauer EC, Kronbeck N, Spitzer RM, Leidescher S, Markaki Y, Mentele E, Regnard C, Schneider K, Takahashi D, Kusakabe M, Vardabasso C, Zink LM, Straub T, Bernstein E, Harata M, Leonhardt H, Mann M, Rupp RA, Hake SB.

EMBO J. 2017 Aug 1;36(15):2263-2279. doi: 10.15252/embj.201695757. Epub 2017 Jun 23.

3.

H3.Y discriminates between HIRA and DAXX chaperone complexes and reveals unexpected insights into human DAXX-H3.3-H4 binding and deposition requirements.

Zink LM, Delbarre E, Eberl HC, Keilhauer EC, Bönisch C, Pünzeler S, Bartkuhn M, Collas P, Mann M, Hake SB.

Nucleic Acids Res. 2017 Jun 2;45(10):5691-5706. doi: 10.1093/nar/gkx131.

4.

Variants of core histones and their roles in cell fate decisions, development and cancer.

Buschbeck M, Hake SB.

Nat Rev Mol Cell Biol. 2017 May;18(5):299-314. doi: 10.1038/nrm.2016.166. Epub 2017 Feb 1. Review.

PMID:
28144029
5.

Histone variant H2A.Z.2: A novel driver of melanoma progression.

Vardabasso C, Hake SB, Bernstein E.

Mol Cell Oncol. 2015 Sep 16;3(2):e1073417. doi: 10.1080/23723556.2015.1073417. eCollection 2016 Mar.

6.

Histone variants: nuclear function and disease.

Zink LM, Hake SB.

Curr Opin Genet Dev. 2016 Apr;37:82-89. doi: 10.1016/j.gde.2015.12.002. Epub 2016 Jan 28. Review.

PMID:
26826795
7.

Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.

Vardabasso C, Gaspar-Maia A, Hasson D, Pünzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B, Verma A, Mann M, Hernando E, Hake SB, Bernstein E.

Mol Cell. 2015 Jul 2;59(1):75-88. doi: 10.1016/j.molcel.2015.05.009. Epub 2015 Jun 4.

8.

The CENP-T C-terminus is exclusively proximal to H3.1 and not to H3.2 or H3.3.

Abendroth C, Hofmeister A, Hake SB, Kamweru PK, Miess E, Dornblut C, Küffner I, Deng W, Leonhardt H, Orthaus S, Hoischen C, Diekmann S.

Int J Mol Sci. 2015 Mar 12;16(3):5839-63. doi: 10.3390/ijms16035839.

9.

Structure-guided mutational analysis reveals the functional requirements for product specificity of DOT1 enzymes.

Dindar G, Anger AM, Mehlhorn C, Hake SB, Janzen CJ.

Nat Commun. 2014 Nov 12;5:5313. doi: 10.1038/ncomms6313.

PMID:
25387577
10.

Getting down to the core of histone modifications.

Jack AP, Hake SB.

Chromosoma. 2014 Aug;123(4):355-71. doi: 10.1007/s00412-014-0465-x. Epub 2014 May 2. Review.

PMID:
24789118
11.

The histone variant H2A.Bbd is enriched at sites of DNA synthesis.

Sansoni V, Casas-Delucchi CS, Rajan M, Schmidt A, Bönisch C, Thomae AW, Staege MS, Hake SB, Cardoso MC, Imhof A.

Nucleic Acids Res. 2014 Jun;42(10):6405-20. doi: 10.1093/nar/gku303. Epub 2014 Apr 20.

12.

Histone glutamine methylation afFACTing rDNA transcription.

Leonhardt H, Hake SB.

Cell Res. 2014 Mar;24(3):261-2. doi: 10.1038/cr.2014.22. Epub 2014 Feb 14.

13.

Histone h3 glutathionylation in proliferating mammalian cells destabilizes nucleosomal structure.

García-Giménez JL, Òlaso G, Hake SB, Bönisch C, Wiedemann SM, Markovic J, Dasí F, Gimeno A, Pérez-Quilis C, Palacios O, Capdevila M, Viña J, Pallardó FV.

Antioxid Redox Signal. 2013 Oct 20;19(12):1305-20. doi: 10.1089/ars.2012.5021. Epub 2013 May 21.

14.

H3K56me3 is a novel, conserved heterochromatic mark that largely but not completely overlaps with H3K9me3 in both regulation and localization.

Jack AP, Bussemer S, Hahn M, Pünzeler S, Snyder M, Wells M, Csankovszki G, Solovei I, Schotta G, Hake SB.

PLoS One. 2013;8(2):e51765. doi: 10.1371/journal.pone.0051765. Epub 2013 Feb 22.

15.

Histone H2A variants in nucleosomes and chromatin: more or less stable?

Bönisch C, Hake SB.

Nucleic Acids Res. 2012 Nov;40(21):10719-41. doi: 10.1093/nar/gks865. Epub 2012 Sep 21. Review.

16.

A unified phylogeny-based nomenclature for histone variants.

Talbert PB, Ahmad K, Almouzni G, Ausió J, Berger F, Bhalla PL, Bonner WM, Cande WZ, Chadwick BP, Chan SW, Cross GA, Cui L, Dimitrov SI, Doenecke D, Eirin-López JM, Gorovsky MA, Hake SB, Hamkalo BA, Holec S, Jacobsen SE, Kamieniarz K, Khochbin S, Ladurner AG, Landsman D, Latham JA, Loppin B, Malik HS, Marzluff WF, Pehrson JR, Postberg J, Schneider R, Singh MB, Smith MM, Thompson E, Torres-Padilla ME, Tremethick DJ, Turner BM, Waterborg JH, Wollmann H, Yelagandula R, Zhu B, Henikoff S.

Epigenetics Chromatin. 2012 Jun 21;5:7. doi: 10.1186/1756-8935-5-7.

17.

Versatile toolbox for high throughput biochemical and functional studies with fluorescent fusion proteins.

Pichler G, Jack A, Wolf P, Hake SB.

PLoS One. 2012;7(5):e36967. doi: 10.1371/journal.pone.0036967. Epub 2012 May 11.

18.

H2A.Z.2.2 is an alternatively spliced histone H2A.Z variant that causes severe nucleosome destabilization.

Bönisch C, Schneider K, Pünzeler S, Wiedemann SM, Bielmeier C, Bocola M, Eberl HC, Kuegel W, Neumann J, Kremmer E, Leonhardt H, Mann M, Michaelis J, Schermelleh L, Hake SB.

Nucleic Acids Res. 2012 Jul;40(13):5951-64. Epub 2012 Mar 29.

19.

ATRX-mediated chromatin association of histone variant macroH2A1 regulates α-globin expression.

Ratnakumar K, Duarte LF, LeRoy G, Hasson D, Smeets D, Vardabasso C, Bönisch C, Zeng T, Xiang B, Zhang DY, Li H, Wang X, Hake SB, Schermelleh L, Garcia BA, Bernstein E.

Genes Dev. 2012 Mar 1;26(5):433-8. doi: 10.1101/gad.179416.111.

20.

Proteomic interrogation of human chromatin.

Torrente MP, Zee BM, Young NL, Baliban RC, LeRoy G, Floudas CA, Hake SB, Garcia BA.

PLoS One. 2011;6(9):e24747. doi: 10.1371/journal.pone.0024747. Epub 2011 Sep 14.

21.

The histone methyltransferase Dot1 is required for DNA damage repair and proper development in Dictyostelium.

Müller-Taubenberger A, Bönisch C, Fürbringer M, Wittek F, Hake SB.

Biochem Biophys Res Commun. 2011 Jan 28;404(4):1016-22. doi: 10.1016/j.bbrc.2010.12.101. Epub 2010 Dec 25.

PMID:
21187070
22.

Identification and characterization of two novel primate-specific histone H3 variants, H3.X and H3.Y.

Wiedemann SM, Mildner SN, Bönisch C, Israel L, Maiser A, Matheisl S, Straub T, Merkl R, Leonhardt H, Kremmer E, Schermelleh L, Hake SB.

J Cell Biol. 2010 Sep 6;190(5):777-91. doi: 10.1083/jcb.201002043.

23.

Proteome-wide prediction of acetylation substrates.

Basu A, Rose KL, Zhang J, Beavis RC, Ueberheide B, Garcia BA, Chait B, Zhao Y, Hunt DF, Segal E, Allis CD, Hake SB.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13785-90. doi: 10.1073/pnas.0906801106. Epub 2009 Aug 3.

24.

Chromatin proteomics and epigenetic regulatory circuits.

Bönisch C, Nieratschker SM, Orfanos NK, Hake SB.

Expert Rev Proteomics. 2008 Feb;5(1):105-19. doi: 10.1586/14789450.5.1.105. Review.

PMID:
18282127
25.

Histone modifications in Trypanosoma brucei.

Mandava V, Fernandez JP, Deng H, Janzen CJ, Hake SB, Cross GA.

Mol Biochem Parasitol. 2007 Nov;156(1):41-50. Epub 2007 Jul 17.

26.

Extraction, purification and analysis of histones.

Shechter D, Dormann HL, Allis CD, Hake SB.

Nat Protoc. 2007;2(6):1445-57.

PMID:
17545981
27.

Linking the epigenetic 'language' of covalent histone modifications to cancer.

Hake SB, Xiao A, Allis CD.

Br J Cancer. 2007;96 Suppl:R31-9.

PMID:
17393583
28.

Organismal differences in post-translational modifications in histones H3 and H4.

Garcia BA, Hake SB, Diaz RL, Kauer M, Morris SA, Recht J, Shabanowitz J, Mishra N, Strahl BD, Allis CD, Hunt DF.

J Biol Chem. 2007 Mar 9;282(10):7641-55. Epub 2006 Dec 28.

29.

Identification of histone H3 lysine 36 acetylation as a highly conserved histone modification.

Morris SA, Rao B, Garcia BA, Hake SB, Diaz RL, Shabanowitz J, Hunt DF, Allis CD, Lieb JD, Strahl BD.

J Biol Chem. 2007 Mar 9;282(10):7632-40. Epub 2006 Dec 21.

30.

The nucleosome: a little variation goes a long way.

Bernstein E, Hake SB.

Biochem Cell Biol. 2006 Aug;84(4):505-17. Review.

PMID:
16936823
31.
32.

Unusual histone modifications in Trypanosoma brucei.

Janzen CJ, Fernandez JP, Deng H, Diaz R, Hake SB, Cross GA.

FEBS Lett. 2006 Apr 17;580(9):2306-10. Epub 2006 Mar 24.

33.

Histone H3 variants and their potential role in indexing mammalian genomes: the "H3 barcode hypothesis".

Hake SB, Allis CD.

Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6428-35. Epub 2006 Mar 29. Review.

34.
35.

Expression patterns and post-translational modifications associated with mammalian histone H3 variants.

Hake SB, Garcia BA, Duncan EM, Kauer M, Dellaire G, Shabanowitz J, Bazett-Jones DP, Allis CD, Hunt DF.

J Biol Chem. 2006 Jan 6;281(1):559-68. Epub 2005 Nov 2.

36.

Modifications of human histone H3 variants during mitosis.

Garcia BA, Barber CM, Hake SB, Ptak C, Turner FB, Busby SA, Shabanowitz J, Moran RG, Allis CD, Hunt DF.

Biochemistry. 2005 Oct 4;44(39):13202-13.

PMID:
16185088
37.

Serine 31 phosphorylation of histone variant H3.3 is specific to regions bordering centromeres in metaphase chromosomes.

Hake SB, Garcia BA, Kauer M, Baker SP, Shabanowitz J, Hunt DF, Allis CD.

Proc Natl Acad Sci U S A. 2005 May 3;102(18):6344-9. Epub 2005 Apr 25.

38.

Linking the epigenetic 'language' of covalent histone modifications to cancer.

Hake SB, Xiao A, Allis CD.

Br J Cancer. 2004 Feb 23;90(4):761-9. Review.

39.

Importance of class II transactivator leucine-rich repeats for dominant-negative function and nucleo-cytoplasmic transport.

Camacho-Carvajal MM, Klingler S, Schnappauf F, Hake SB, Steimle V.

Int Immunol. 2004 Jan;16(1):65-75.

PMID:
14688062
40.

Comparison of the transcriptional regulation of classical and non-classical MHC class II genes.

Hake SB, Tobin HM, Steimle V, Denzin LK.

Eur J Immunol. 2003 Sep;33(9):2361-71.

41.

N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA.

Schnappauf F, Hake SB, Camacho Carvajal MM, Bontron S, Lisowska-Grospierre B, Steimle V.

Eur J Immunol. 2003 Aug;33(8):2337-47.

42.

Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO.

Glazier KS, Hake SB, Tobin HM, Chadburn A, Schattner EJ, Denzin LK.

J Exp Med. 2002 Apr 15;195(8):1063-9. Erratum in: J Exp Med. 2003 Dec 1;198(11):1765.

43.

Supplemental Content

Support Center